Oligosymptomatic clinical course of the hepatitis C virus infection with manifesting complications in intravenous drug abuser (own clinical observations)
No. 4 (2019), HEPATOLOGY
No. 4 (2019)

Oligosymptomatic clinical course of the hepatitis C virus infection with manifesting complications in intravenous drug abuser (own clinical observations)

HEPATOLOGY
Published December 20, 2019
V.M. Rudichenko
Національний медичний університет ім. О.О. Богомольця, м. Київ
V.I. Reizin
Київська міська клінічна лікарня № 8
M.O. Kushnerova
ТОВ «Доктор Сем»
L.A. Stadniuk
Національна медична академія післядипломної освіти ім. П.Л. Шупика, м. Київ
pdf (Українська)

Keywords

hepatitis C virus infection, hepatitis C virus, liver cirrhosis, hepatocellular carcinoma.

How to Cite

Rudichenko, V., Reizin, V., Kushnerova, M., & Stadniuk, L. (2019). Oligosymptomatic clinical course of the hepatitis C virus infection with manifesting complications in intravenous drug abuser (own clinical observations). The Practitioner, (4), 37-43. Retrieved from https://plr.com.ua/index.php/journal/article/view/498
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Currently in the world there are more, than 180 mln of persons living with chronic hepatitis C virus infection. Such people are in the great risk of cirrhosis, end-stage liver disease and hepatocellular carcinoma. Additionally 3-4 mln people receive new infection each year. In a big amount of patients with active virus replication cirrhosis and hepatocellular carcinoma develop during two-three decades. We believe appropriate in the process of education in state and English language for students and interns during practical clinical classes in family medicine-general practice to use cases of widely spread and rare diseases with description of the treatment. Article contains the results of own clinical observations of oligosymptomatic clinical course of the hepatitis C virus infection with
manifesting serious complications in intravenous drug abuser.

pdf (Українська)

References

1. Рейзін В.І., Рудіченко В.М., Хантіль Н.М. Моніторинг стану та лікування хворого з верифікованим гепатитом С із ускладненнями: власні клінічні спостереження // Ліки України. — 2018. — № 4. — С. 24-29.
2. Рудіченко В.М., Кушнєрова М.О. Атипові прояви подагри у загальній практиці-сімейній медицині: власні клінічні спостереження та дані літератури // Сімейна медицина. — 2018. — № 6. — С. 26-29.
3. Agha S., Tanaka Y., Saudy N. et al. Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan // J. Med. Virol. — 2004. — Vol. 73. — P. 216-222.
4. Alter M.J. Epidemiology of hepatitis C virus infection // World J. Gastroenterol. — 2007. — Vol. 13. — P. 2436-2441.
5. Amin J., Law M.G., Bartlett M. et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study // Lancet. — 2006. — Vol. 368. — P. 938-945.
6. Amoroso P., Rapicetta M., Tosti M.E. et al. Correlation between virus genotype and chronicity rate in acute hepatitis C // J. Hepatol. — 1998. — Vol. 28. — P. 939-944.
7. Bukh J., Miller R.H., Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes // Semin. Liver Dis. — 1995. — Vol. 15. — P. 41-63.
8. Choo Q.L. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome // Science. — 1989. — Vol. 244. — P. 359-362.
9. Cooke G.S., Lemoine M, Thursz M. et al. Viral hepatitis and the Global Burden of Disease: a need to regroup // J. Viral. Hepatol. — 2013. — Vol. 20. — P. 600-601.
10. Farci P., Shimoda A., Coiana A. et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies // Science. — 2000. — Vol. 288. — P. 339-344.
11. Farci P., Strazzera R., Alter H.J. et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome // Proc. Natl. Acad. Sci. USA. — 2002. — Vol. 99. — P. 3081-3086.
12. Feinstone S.M., Kapikian A.Z., Purcell R.H. et al. Transfusion–associated hepatitis not due to viral hepatitis type A or B // N. Engl. J. Med. — 1975. — Vol. 292. — P. 767-770.
13. GBD2013. Mortality and causes of death collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. — 2015. — Vol. 385. — P. 117-171.
14. Jackowiak P., Kuls K., Budzko L. et al. Phylogeny and molecular evolution of the hepatitis C virus // Infect. Genet. Evol. — 2014. — Vol. 21. — P. 67-82.
15. Kao J.H., Chen P.J., Lai M.Y. et al. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease // J. Clin. Gastroenterol. 1995. — Vol. 21. — P. 233-237.

Downloads

Download data is not yet available.